Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11291219 | 0.85 | ALDH1A1 (0.43) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL15358736 | 0.83 | ALDH1A1 (0.53) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL16640696 | 0.80 | HTR7 (0.43) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL3315497 | 0.79 | SIRT6 (0.66) | ALDH1A1HTTKDM4EMAPTMAPK1 | |
| SCHEMBL13362139 | 0.79 | GAA (0.45) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL2234370 | 0.78 | GAA (0.47) | GAARAD52HTR7HSD17B10ADORA2B | |
| SCHEMBL13362045 | 0.77 | MAPT (0.41) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL3309196 | 0.77 | GAA (0.40) | GAARAD52ALDH1A1HTR7HTT | |
| SCHEMBL15651516 | 0.77 | MAPT (0.53) | GAARAD52ALDH1A1HTTKDM4E | |
| SCHEMBL438444 | 0.77 | MAPT (0.63) | GAAALDH1A1HTTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | TMEM97 3258/4885GAA 742/4885RAD52 3338/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | TMEM97 4051/4885GAA 940/4885RAD52 3930/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | TMEM97 3258/4885GAA 742/4885RAD52 3338/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | TMEM97 3452/4885GAA 698/4885RAD52 3129/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | TMEM97 3170/4885GAA 1003/4885RAD52 1276/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | TMEM97 3452/4885GAA 698/4885RAD52 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.